Mangoceuticals (NASDAQ:MGRX – Get Free Report) and Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, institutional ownership and risk.
Institutional and Insider Ownership
56.7% of Mangoceuticals shares are owned by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are owned by institutional investors. 16.0% of Mangoceuticals shares are owned by company insiders. Comparatively, 22.3% of Lyell Immunopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Mangoceuticals and Lyell Immunopharma”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Mangoceuticals | $460,000.00 | 11.97 | -$8.71 million | ($3.56) | -0.09 |
| Lyell Immunopharma | $36,000.00 | 13,731.71 | -$274.45 million | ($16.30) | -1.30 |
Mangoceuticals has higher revenue and earnings than Lyell Immunopharma. Lyell Immunopharma is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Mangoceuticals and Lyell Immunopharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mangoceuticals | 1 | 0 | 0 | 0 | 1.00 |
| Lyell Immunopharma | 1 | 0 | 2 | 0 | 2.33 |
Lyell Immunopharma has a consensus price target of $39.50, suggesting a potential upside of 86.23%. Given Lyell Immunopharma’s stronger consensus rating and higher probable upside, analysts plainly believe Lyell Immunopharma is more favorable than Mangoceuticals.
Profitability
This table compares Mangoceuticals and Lyell Immunopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mangoceuticals | -4,253.43% | -114.63% | -106.42% |
| Lyell Immunopharma | -762,355.56% | -90.52% | -70.22% |
Volatility and Risk
Mangoceuticals has a beta of 2.54, suggesting that its stock price is 154% more volatile than the S&P 500. Comparatively, Lyell Immunopharma has a beta of -0.06, suggesting that its stock price is 106% less volatile than the S&P 500.
Summary
Lyell Immunopharma beats Mangoceuticals on 8 of the 14 factors compared between the two stocks.
About Mangoceuticals
Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
About Lyell Immunopharma
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Receive News & Ratings for Mangoceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mangoceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
